Summary and conclusion

Symptoms of anxiety and post-traumatic stress are going to be prevalent as a consequence of the COVID-19 pandemic, particularly in those most closely affected by the disease, and in those with existing anxiety conditions. Current anti-anxiety medications possess significant unwanted side-effects, including strong drug dependence and withdrawal syndromes. CBD is already being evaluated as a potential treatment during the active coronavirus disease phase, and we suggest that the preclinical and clinical evidence base supports the hypothesis that CBD could be a novel pharmacological option for treating COVID-related anxiety disorders. CBD could be more preferable compared to some of the medicines currently available with respect to its safety and side effect profile.